Catalog No.: PC-49727Not For Human Use, Lab Use Only.
YTK-2205 (YTK2205) is a small molecule p62 agonist targeting ZZ domain, induces selective autophagy activation, YTK-2205 augments the translocation of p62 to mitochondria, targeting their lysosomal degradation.
YTK-2205 (YTK2205) is a small molecule p62 agonist targeting ZZ domain, induces selective autophagy activation, YTK-2205 augments the translocation of p62 to mitochondria, targeting their lysosomal degradation.
YTK-2205 (20 mg/kg) exerts therapeutic efficacy in paracetamol-induced liver damage, YTK-2205 successfully induced in vivo p62 oligomerization in livers from paracetamol-treated mice.
YTK-2205 limits JNK phosphorylation without altering either NRF2 pathway or mitochondrial RIPK1 translocation during paracetamol-induced hepatotoxicity.
YTK-2205 efficiently reduces ubiquitinated proteins in vivo by promoting selective autophagy, selectively accelerated the autophagic removal of damaged parts of the mitochondrion and ER.
YTK-2205 promotes p62-mediated ER-phagy and mitophagy in paracetamol-loaded primary murine hepatocytes.
Physicochemical Properties
M.Wt
391.51
Formula
C25H29NO3
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
2-((3,4-diphenethoxybenzyl)amino)ethan-1-ol
References
1. Hee-Yeon Kim, et al. Br J Pharmacol. 2022 Dec 7. doi: 10.1111/bph.16004.
